EB1A Approved for a Physician-Scientist Advancing Clinical Research in Cardiovascular and Infectious Diseases

Posted by wegreened on July 4, 2025 in EB1 Green Card, General Medicine (Public Health, Clinical Research, Infectious Diseases, Vaccines, Virology, Epidemiology, Clinical Psychology, Psychiatry)

Client’s Testimonial:

“I am delighted to express my utmost satisfaction with the overall experience. The team exhibited exceptional professionalism, displaying comprehensive knowledge in every aspect and consistently delivering prompt responses to all inquiries. My level of satisfaction is exceedingly high. Thank you, Chen Immigration Attorneys.”

On March 12^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for an ACGME Cardiology Fellow in the Field of Medicine and Healthcare (Approval Notice).

General Field: Medicine and Healthcare

Position at the Time of Case Filing: ACGME Cardiology Fellow

Country of Origin: Pakistan

State of Residence at the Time of Filing: Ohio

Approval Notice Date: March 12^th, 2025

Processing Time: 2 months, 22 days (Premium Processing Requested)

Case Summary:

Our client, a physician-scientist from Pakistan, approached North America Immigration Law Group (NAILG) to file an I-140 petition under the EB1A category. His petition showcased significant scholarly contributions to cardiovascular medicine, particularly in clinical outcomes research and evidence-based treatment of complex cardiovascular and systemic diseases. With a focused legal strategy highlighting both scientific merit and real-world clinical impact, the case was approved without a Request for Evidence (RFE).

Transforming Cardiac and COVID-Related Clinical Practice

The client’s research spans numerous high-impact topics within internal medicine and cardiology, including the evaluation of transcatheter aortic valve implantation (TAVI), degenerative bioprosthetic mitral valve disease, and clinical risk factors for COVID-19 severity and mortality. His studies have contributed to improved surgical decision-making, disease risk prediction, and treatment evaluation in diverse patient populations.

By publishing comparative effectiveness studies and systematic reviews, he has supported the development of data-driven clinical protocols and patient-centered care in cardiology and beyond.

A Recognized Leader in Cardiovascular Research

● 21 peer-reviewed journal publications and 21 scientific abstracts ● Over 120 citations across clinical medicine, cardiology, and infectious disease research ● 13 confirmed peer reviews for high-impact medical journals ● Multiple articles ranked among the top 10% and 1% most cited in Clinical Medicine for their year of publication

His work has been cited by researchers worldwide and applied in global studies focused on COVID-19 comorbidities, cardiovascular procedure outcomes, and hospital-level care analytics.

Here is a compelling excerpt from one of the recommendation letters that highlights how the client’s research benefits the United States:

“[Client’s] research has profound implications for public health, particularly through his analysis of COVID-19 comorbidities and the identification of high-risk groups. By proposing targeted interventions, his work supports evidence-based policy decisions, improves patient outcomes, and aids resource allocation to manage viral spread. Additionally, his findings on hydatid cyst disease enhance clinical diagnostics and strengthen practitioner awareness of rare conditions.”

Notable Scientific Contributions:

The client’s research has advanced treatment strategies for cardiac and infectious diseases. He evaluated valve-in-valve TAVI procedures, identified key predictors of COVID-19 mortality, and developed tools for assessing bleeding risk after cardiac interventions. His findings inform clinical guidelines and surgical decision-making. These contributions are widely cited and applied in global healthcare research.

NAILG’s Legal Strategy: Building the Case for Extraordinary Ability

We argued that the client’s case met the EB1A standard by emphasizing:

● His original scientific contributions of major significance in clinical and translational medicine ● A strong record of peer-reviewed publications and international citations ● Demonstrated recognition as an expert through formal peer review invitations ● Adoption of his findings by independent researchers across more than 25 countries

Expert letters further corroborated his role in shaping cardiovascular disease management and pandemic response in the medical field.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%